What is the most appropriate pharmacologic treatment for a middle‑aged woman with chronic insomnia, panic disorder currently on clonazepam, PTSD, and who has not responded to trazodone or mirtazapine?

Best Pharmacologic Option for Insomnia in Patient on Clonazepam with Panic Disorder and PTSD

For this patient already on clonazepam for panic disorder with comorbid PTSD who has failed trazodone and mirtazapine, I recommend eszopiclone (2-3 mg) or low-dose doxepin (3-6 mg) as the next pharmacologic intervention.

Rationale Based on Guidelines and Evidence

The 2017 American Academy of Sleep Medicine (AASM) guidelines provide clear direction here. Eszopiclone receives a positive recommendation for both sleep onset and sleep maintenance insomnia 1, while low-dose doxepin (3-6 mg) is specifically recommended for sleep maintenance insomnia 1. Critically, the AASM explicitly recommends against using trazodone for insomnia 1, which validates that this patient has already appropriately failed an evidence-poor option.

Why These Options Over Others

Eszopiclone (First Choice)

• Addresses both sleep onset and maintenance 1
• Has demonstrated efficacy in patients with comorbid psychiatric conditions, including mood and anxiety disorders 2
• The 2016 American College of Physicians guideline identified eszopiclone as one of only three agents (along with zolpidem and suvorexant) with moderate-strength evidence for improving global and sleep outcomes 3
• Dosing: Start 2 mg, can increase to 3 mg 1

Low-Dose Doxepin (Alternative)

• Specifically effective for sleep maintenance if that's the primary complaint 1
• Unique mechanism (histamine H1 antagonism at low doses) avoids adding another GABAergic agent
• Dosing: 3-6 mg at bedtime 1
• Recent evidence supports this as a first-line pharmacologic option 4

Critical Considerations for This Specific Patient

The Clonazepam Issue

This patient is already on a benzodiazepine (clonazepam) for panic disorder 5. Adding another GABAergic agent requires caution but is not contraindicated. The guidelines note that eszopiclone and other benzodiazepine receptor agonists (BzRAs) have demonstrated efficacy, though observational data suggest associations with cognitive impairment, falls, and potentially dementia with long-term use 3. However, given treatment failure with non-GABAergic options, a BzRA remains reasonable.

PTSD-Specific Considerations

The literature on PTSD-related insomnia suggests several points:

• Prazosin has shown promise specifically for PTSD-related nightmares and insomnia in small studies 6, though this wasn't included in the AASM insomnia guidelines
• Eszopiclone has been studied in PTSD populations with positive results 7
• Benzodiazepines alone are ineffective for PTSD-related sleep disturbances 8, 6

Why Not Other Options

Suvorexant/Orexin Antagonists: While recommended by AASM for sleep maintenance 1, these are newer with less data in complex psychiatric populations. Consider as third-line.

Ramelteon: Only effective for sleep onset, not maintenance 1, and has very low efficacy overall.

Zolpidem: Reasonable alternative to eszopiclone 1, but shorter half-life makes it less ideal if sleep maintenance is an issue. Standard dose is 10 mg, though FDA recommends 5 mg for women 3.

Additional benzodiazepines (temazepam, triazolam): Not recommended given already on clonazepam; would simply add to benzodiazepine burden 1.

Practical Implementation Algorithm

1. Determine primary sleep complaint:

   • Predominantly sleep onset → Eszopiclone 2 mg or zolpidem
   • Predominantly sleep maintenance → Eszopiclone 2-3 mg or doxepin 3-6 mg
   • Mixed → Eszopiclone 2-3 mg

2. Start with eszopiclone 2 mg at bedtime

   • Reassess after 1 week
   • Can increase to 3 mg if partial response
   • Monitor for next-day sedation, especially given concurrent clonazepam

3. If eszopiclone fails or not tolerated, switch to doxepin 3-6 mg

4. If both fail, consider:

   • Suvorexant 10 mg (can increase to 20 mg)
   • Prazosin specifically for PTSD-related nightmares (start 1 mg, titrate to 2-15 mg)
   • Referral for cognitive behavioral therapy for insomnia (CBT-I), which should be considered regardless

Common Pitfalls to Avoid

• Don't continue ineffective medications: The patient has already failed trazodone and mirtazapine—both lack strong evidence for insomnia 1, 9
• Don't add another benzodiazepine: The patient is already on clonazepam; adding temazepam or triazolam just increases benzodiazepine load without addressing the insomnia mechanism differently
• Don't ignore the PTSD component: If nightmares are prominent, prazosin deserves strong consideration despite not being in the AASM insomnia guidelines 8, 6
• Set expectations for short-term use: All hypnotics should ideally be time-limited while addressing underlying contributors 4
• Monitor for cognitive/behavioral changes: FDA warnings emphasize risks of complex sleep behaviors and next-day impairment, particularly relevant given concurrent clonazepam 3